Skip to main content

Biotechnology ETFs Rally on Sarepta FDA Drug Approval

Sarepta Therapeutics (NasdaqGS: SRPT) surged Monday and lifted biotechnology-related exchange traded funds after the Food and Drug Administration approved the Duchenne muscular dystrophy drug eteplirsen. Leading the charge in the ETF space on Monday, the BioShares Biotechnology Clinical Trials Fund...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.